Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination

Oncoimmunology. 2013 Mar 1;2(3):e23430. doi: 10.4161/onci.23430.


Accumulating evidence demonstrates the importance of CD4+ T cells in antitumor immune responses. Identifying promiscuous MHC class II-binding peptides derived from relevant tumor-associated antigens that specifically target CD4+ helper T cells in vivo represent a powerful approach to fully exploit these cells for anticancer immunotherapy.

Keywords: CD4 T cell; cancer vaccine; helper peptide; immunotherapy; telomerase.